Dr Todd J Pesek, MD | |
5555 Mayfield Rd, Lyndhurst, OH 44124-2939 | |
(440) 995-0555 | |
Not Available |
Full Name | Dr Todd J Pesek |
---|---|
Gender | Male |
Speciality | General Practice |
Location | 5555 Mayfield Rd, Lyndhurst, Ohio |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1669627816 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 35.091001 (Ohio) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Todd J Pesek, MD 5555 Mayfield Rd, Lyndhurst, OH 44124-2939 Ph: (440) 995-0555 | Dr Todd J Pesek, MD 5555 Mayfield Rd, Lyndhurst, OH 44124-2939 Ph: (440) 995-0555 |
News Archive
Studies on mice reveal that a special protein in the brain's tiniest blood vessels may affect the risk of stroke. Peter Carlsson, professor in genetics at the University of Gothenburg, and his research team are publishing new research findings in the journal Developmental Cell about how the blood-brain barrier develops and what makes the capillaries in the brain different from small blood vessels in other organs.
Idaho Technology, Inc. (ITI) has been granted Performance Tested Methods Status by the AOAC Research Institute (Certificate No. 100901) for its E.coli O157:H7 test used with the R.A.P.I.D.® LT Food Security System (FSS). The assay uses real-time PCR technology to identify the presence of E.coli O157:H7 in raw ground beef and uncooked spinach food samples.
St. Jude Medical, Inc., a global medical device company, today announced that it has received European CE Mark approval for its Accent MRI™ pacemaker and Tendril MRI™ lead. The system, designed and tested for safe use in a Magnetic Resonance Imaging (MRI) environment and approved as MR-Conditional, allows patients to undergo full-body, high-resolution MRI scans.
Keryx Biopharmaceuticals, Inc. (the "Company") today announced that an article entitled "Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenstrom's Macroglobulinemia," reporting Phase 2 data demonstrating the single agent activity of KRX-0401 (Perifosine) for the treatment of advanced Waldenstrom's Macroglobulinemia ("Waldenstrom's"), will appear in the February 1, 2010 issue of Clinical Cancer Research.
› Verified 3 days ago